Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 3,283

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Lung cancer: current therapies and new targeted treatments

Open access
Hirsch, Fred R, Scagliotti, Giorgio V, Mulshine, James L, Kwon, Regina, Curran, Walter J, Wu, Yi-Long, Paz-Ares, Luis·2017·The Lancet
DOI 10.1016/s0140-6736(16)30958-8
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(16)30958-8

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Research works printed but not linked: 102

  1. Horeweg, 2014, Lung cancer probability in patients with CT-detected pulmonary nodules: a pre-specified analysis of data from the NELSON trial of low-dose CT screening, Lancet Oncol, 15, 1332, 10.1016/S1470-2045(14)70389-4 · DOI · Paper page
  2. Field, 2015, UK lung cancer RCT pilot screening trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening, Thorax, 71, 161, 10.1136/thoraxjnl-2015-207140 · DOI · Paper page
  3. Henschke, 2013, Definition of a positive test result in computed tomography screening for lung cancer: a cohort study, Ann Intern Med, 158, 246, 10.7326/0003-4819-158-4-201302190-00004 · DOI · Paper page
  4. Kazerooni, 2015, ACR CT accreditation program and the lung cancer screening program designation, J Am Coll Radiol, 12, 38, 10.1016/j.jacr.2014.10.002 · DOI
  5. Pinsky, 2015, Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment, Ann Intern Med, 162, 485, 10.7326/M14-2086 · DOI · Paper page
  6. Frank, 2013, Radiation risk of lung cancer screening, Semin Respir Crit Care Med, 34, 738, 10.1055/s-0033-1358615 · doi:10.1055/s-0033-1358615
  7. Yoshizawa, 2011, Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases, Mod Pathol, 24, 653, 10.1038/modpathol.2010.232 · DOI · Paper page
  8. Yankelevitz, 2015, CT screening for lung cancer: nonsolid nodules in baseline and annual repeat rounds, Radiology, 277, 555, 10.1148/radiol.2015142554 · DOI · Paper page
  9. Mulshine, 2014, Issues with implementing a high-quality lung cancer screening program, CA Cancer J Clin, 64, 352, 10.3322/caac.21239 · DOI
  10. Flores, 2014, Balancing curability and unnecessary surgery in the context of computed tomography screening for lung cancer, J Thorac Cardiovasc Surg, 147, 1619, 10.1016/j.jtcvs.2013.11.001 · doi:10.1016/j.jtcvs.2013.11.001
  11. Villanti, 2013, A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions, PLoS One, 8, e71379, 10.1371/journal.pone.0071379 · DOI · Paper page
  12. Ostroff, 2015, Readiness of lung cancer screening sites to deliver smoking cessation treatment: current practices, organizational priority, and perceived barriers, Nicotine Tob Res, 18, 1067, 10.1093/ntr/ntv177 · DOI
  13. Zhou, 2015, China national lung cancer screening guideline with low-dose computed tomography (2015 version), Thorac Cancer, 6, 812, 10.1111/1759-7714.12287 · DOI
  14. 2016, Recommendations on screening for lung cancer, CMAJ, 188, 425, 10.1503/cmaj.151421 · DOI · Paper page
  15. Bailar, 1984, Screening for lung cancer—where are we now?, Am Rev Respir Dis, 130, 541
  16. Vansteenkiste, 2014, 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up, Ann Oncol, 25, 1462, 10.1093/annonc/mdu089 · DOI · Paper page
  17. Cao, 2013, Video-assisted thoracic surgery versus open thoracotomy for non-small cell lung cancer: a meta-analysis of propensity score-matched patients, Interact Cardiovasc Thorac Surg, 16, 244, 10.1093/icvts/ivs472 · doi:10.1093/icvts/ivs472
  18. Pignon, 2008, Lung adjuvant cisplatin evaluation: a pooled analysis from the LACE Collaborative Group, J Clin Oncol, 26, 3552, 10.1200/JCO.2007.13.9030 · DOI · Paper page
  19. 2014, Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data, Lancet, 383, 1561, 10.1016/S0140-6736(13)62159-5 · DOI · Paper page
  20. Kelly, 2015, Adjuvant erlotinib versus placebo in patients with stage IB–IIIA non-small cell lung cancer (RADIANT): a randomized, double-blind, phase III trial, J Clin Oncol, 33, 4007, 10.1200/JCO.2015.61.8918 · DOI · Paper page
  21. Hirsch, 2015, Adjuvant TKIs in NSCLC: what can we learn from RADIANT?, Nat Rev Clin Oncol, 12, 689, 10.1038/nrclinonc.2015.202 · DOI
  22. Wakelee HA, Dahlberg SE, Keller SM, et-al. Randomized phase III trial of adjuvant chemotherapy with or without bevacizumab in resected non-small cell lung cancer (NSCLC): Results of E1505. World Conference on Lung Cancer; Denver, CO, USA; Sept 6–9, 2015. Abstract 1608.
  23. Goss, 2013, Gefitinib versus placebo in completely resected non-small cell lung cancer; result of the NCIC-CTG BR 19 study, J Clin Oncol, 31, 3320, 10.1200/JCO.2013.51.1816 · DOI · Paper page
  24. Timmerman, 2010, Stereotactic body radiation therapy for inoperable early stage lung cancer, JAMA, 303, 1070, 10.1001/jama.2010.261 · DOI · Paper page
  25. Fakiris, 2009, Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study, Int J Radiat Oncol Biol Phys, 75, 677, 10.1016/j.ijrobp.2008.11.042 · DOI · Paper page
  26. Curran, 2011, Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410, J Natl Cancer Inst, 103, 1452, 10.1093/jnci/djr325 · DOI · Paper page
  27. Auperin, 2010, Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer, J Clin Oncol, 28, 2181, 10.1200/JCO.2009.26.2543 · DOI · Paper page
  28. Bradley, 2015, Lancet Oncol, 16, 187, 10.1016/S1470-2045(14)71207-0 · DOI · Paper page
  29. Senan, 2016, PROCLAIM: Randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer, J Clin Oncol, 34, 953, 10.1200/JCO.2015.64.8824 · DOI · Paper page
  30. Jänne, 2013, Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study, Lancet Oncol, 14, 38, 10.1016/S1470-2045(12)70489-8 · DOI · Paper page
  31. Mazières, 2013, Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed in a phase 1/1B trial involving KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): efficacy and biomarker results, J Thorac Oncol, 8, 2922
  32. Marchetti, 2011, Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations, J Clin Oncol, 29, 3574, 10.1200/JCO.2011.35.9638 · DOI · Paper page
  33. Paik, 2011, Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations, J Clin Oncol, 29, 2046, 10.1200/JCO.2010.33.1280 · DOI · Paper page
  34. Kris, 2015, Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors, Ann Oncol, 26, 1421, 10.1093/annonc/mdv186 · DOI · Paper page
  35. Sadiq, 2013, MET as a possible target for non-small-cell lung cancer, J Clin Oncol, 31, 1089, 10.1200/JCO.2012.43.9422 · DOI · Paper page
  36. Paik, 2015, Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping, Cancer Discov, 5, 842, 10.1158/2159-8290.CD-14-1467 · DOI · Paper page
  37. Shaw, 2009, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK, J Clin Oncol, 27, 4247, 10.1200/JCO.2009.22.6993 · DOI · Paper page
  38. Katayama, 2015, Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine, Clin Cancer Res, 21, 2227, 10.1158/1078-0432.CCR-14-2791 · DOI · Paper page
  39. Gainor, 2013, ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer, Clin Cancer Res, 19, 4273, 10.1158/1078-0432.CCR-13-0318 · DOI · Paper page
  40. Gadgeel, 2014, Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study, Lancet Oncol, 15, 1119, 10.1016/S1470-2045(14)70362-6 · DOI · Paper page
  41. Gettinger, 2014, ALK Inhibitor AP26113 in patients with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC): updated efficacy and safety data, Ann Oncol, 25, iv426, 10.1093/annonc/mdu349.71 · DOI
  42. Zou, 2015, PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations, Proc Natl Acad Sci USA, 112, 3493, 10.1073/pnas.1420785112 · DOI · Paper page
  43. Boyle, 2015, ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer, Clin Lung Cancer, 16, 106, 10.1016/j.cllc.2014.10.003 · DOI
  44. Mazières, 2015, Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort, J Clin Oncol, 33, 992, 10.1200/JCO.2014.58.3302 · DOI · Paper page
  45. Awad, 2013, Acquired resistance to crizotinib from a mutation in CD74-ROS1, N Engl J Med, 368, 2395, 10.1056/NEJMoa1215530 · DOI · Paper page
  46. Rolfo, 2014, ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it, Transl Lung Cancer Res, 3, 250
  47. Califano, 2015, Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer, Cancer Treat Rev, 41, 401, 10.1016/j.ctrv.2015.03.009 · DOI
  48. Drilon, 2013, Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas, Cancer Discov, 3, 630, 10.1158/2159-8290.CD-13-0035 · DOI · Paper page
  49. Drilon, 2015, Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers, J Clin Oncol, 33, 8007, 10.1200/jco.2015.33.15_suppl.8007 · doi:10.1200/jco.2015.33.15_suppl.8007
  50. Doebele, 2015, An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101, Cancer Discov, 5, 1049, 10.1158/2159-8290.CD-15-0443 · DOI · Paper page
  51. Camidge, 2014, Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC), J Clin Oncol, 32, 8001, 10.1200/jco.2014.32.15_suppl.8001 · DOI · Paper page
  52. Shigematsu, 2005, Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers, J Natl Cancer Inst, 97, 339, 10.1093/jnci/dji055 · DOI · Paper page
  53. Wu, 2015, First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study, Ann Oncol, 26, 1883, 10.1093/annonc/mdv270 · DOI · Paper page
  54. Piotrowska, 2015, Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor, Cancer Discov, 5, 713, 10.1158/2159-8290.CD-15-0399 · DOI · Paper page
  55. Yang, 2013, Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer, Lung Cancer, 79, 33, 10.1016/j.lungcan.2012.09.016 · DOI · Paper page
  56. Mok, 2015, Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy, Clin Cancer Res, 21, 3196, 10.1158/1078-0432.CCR-14-2594 · DOI · Paper page
  57. Wu, 2013, Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial, Lancet Oncol, 14, 777, 10.1016/S1470-2045(13)70254-7 · DOI · Paper page
  58. Seto, 2014, Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study, Lancet Oncol, 15, 1236, 10.1016/S1470-2045(14)70381-X · DOI · Paper page
  59. Stahel, 2015, Eur J Cancer, 51, S711, 10.1016/S0959-8049(15)30068-X · DOI
  60. Zeng, 2015, Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor, J Med Chem, 58, 8200, 10.1021/acs.jmedchem.5b01073 · DOI
  61. Rikova, 2007, Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer, Cell, 131, 1190, 10.1016/j.cell.2007.11.025 · DOI · Paper page
  62. Kwak, 2010, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, N Engl J Med, 363, 1693, 10.1056/NEJMoa1006448 · DOI · Paper page
  63. Camidge, 2012, Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study, Lancet Oncol, 13, 1011, 10.1016/S1470-2045(12)70344-3 · DOI · Paper page
  64. Kim, 2012, Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer, J Clin Oncol, 30, 7533, 10.1200/JCO.2011.39.9766 · DOI
  65. Costa, 2015, Clinical experience with crizotinib in patients with advanced ALK-rearranged nonsmall-cell lung cancer and brain metastases, J Clin Oncol, 33, 1881, 10.1200/JCO.2014.59.0539 · DOI · Paper page
  66. Doebele, 2012, Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer, Clin Cancer Res, 18, 1472, 10.1158/1078-0432.CCR-11-2906 · DOI · Paper page
  67. Friboulet, 2014, The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer, Cancer Discov, 4, 662, 10.1158/2159-8290.CD-13-0846 · DOI · Paper page
  68. Mok, 2015, ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ), J Clin Oncol, 33, 8059, 10.1200/jco.2015.33.15_suppl.8059 · DOI
  69. Felip, 2015, ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC), J Clin Oncol, 33, 8060, 10.1200/jco.2015.33.15_suppl.8060 · DOI
  70. Seto, 2013, CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study, Lancet Oncol, 14, 590, 10.1016/S1470-2045(13)70142-6 · DOI · Paper page
  71. Nokihara, 2016, Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study, J Clin Oncol, 34, 9008, 10.1200/JCO.2016.34.15_suppl.9008 · doi:10.1200/jco.2016.34.15_suppl.9008
  72. Wang, 2012, RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer, J Clin Oncol, 30, 4352, 10.1200/JCO.2012.44.1477 · DOI · Paper page
  73. Michels, 2016, Clinicopathological characteristics of RET rearranged lung cancer in European patients, J Thorac Oncol, 11, 122, 10.1016/j.jtho.2015.09.016 · DOI · Paper page
  74. Scagliotti, 2015, Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer, J Clin Oncol, 33, 2667, 10.1200/JCO.2014.60.7317 · DOI · Paper page
  75. Spigel, 2014, Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicentre, placebo-controlled METLung (OAM4971g) global trial, J Clin Oncol, 32, 8000, 10.1200/jco.2014.32.15_suppl.8000 · doi:10.1200/jco.2014.32.15_suppl.8000
  76. Planchard, 2015, Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAFV600E mutated (mut) metastatic non-small cell lung cancer (NSCLC), J Clin Oncol, 33, 8006, 10.1200/jco.2015.33.15_suppl.8006 · DOI
  77. Weiss, 2010, Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer, Sci Transl Med, 2, 62ra93, 10.1126/scitranslmed.3001451 · DOI · Paper page
  78. Hammerman, 2011, Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer, Cancer Discov, 1, 78, 10.1158/2159-8274.CD-11-0005 · DOI · Paper page
  79. Bunn, 2016, Small cell lung cancer: can recent advances in biology and molecular biology be translated into improved outcomes?, J Thorac Oncol, 4, 453, 10.1016/j.jtho.2016.01.012 · DOI · Paper page
  80. Pietanza, 2015, Small cell lung cancer: will recent progress lead to improved outcomes?, Clin Cancer Res, 21, 2244, 10.1158/1078-0432.CCR-14-2958 · DOI · Paper page
  81. Almquist, 2016, Multimodality therapy for limited-stage small-cell lung cancer, J Oncol Pract, 12, 111, 10.1200/JOP.2015.009068 · doi:10.1200/jop.2015.009068
  82. Forde, 2014, New strategies in lung cancer: translating immunotherapy into clinical practice, Clin Cancer Res, 20, 1067, 10.1158/1078-0432.CCR-13-0731 · DOI
  83. Vansteenkiste, 2016, Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 17, 822, 10.1016/S1470-2045(16)00099-1 · DOI · Paper page
  84. Quoix, 2016, TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial, Lancet Oncol, 17, 212, 10.1016/S1470-2045(15)00483-0 · DOI · Paper page
  85. Postow, 2015, Immune checkpoint blockade in cancer therapy, J Clin Oncol, 33, 1974, 10.1200/JCO.2014.59.4358 · DOI · Paper page
  86. Rizvi, 2015, Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC), J Clin Oncol, 33, 8032, 10.1200/jco.2015.33.15_suppl.8032 · DOI · Paper page
  87. Gulley, 2015, Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy, J Clin Oncol, 33, 8034, 10.1200/jco.2015.33.15_suppl.8034 · DOI
  88. Gettinger, 2015, Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer, J Clin Oncol, 33, 2004, 10.1200/JCO.2014.58.3708 · DOI · Paper page
  89. Soria, 2015, Efficacy and safety of pembrolizumab (Pembro; MK-3475) for patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC) enrolled in KEYNOTE-001, Ann Oncol, 26, 33LBA
  90. Kerr, 2016, Programmed Death Ligand 1 immunohistochemistry: friend or foe?, Arch Pathol Lab Med, 140, 326, 10.5858/arpa.2015-0522-SA · DOI
  91. Besse, 2015, Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), Eur J Cancer, 51, S717, 10.1016/S0959-8049(16)31938-4 · DOI
  92. Antonia, 2015, Phase I/II study of nivolumab with or without ipilimumab for the treatment of recurrent small cell lung cancer (SCLC): CA209.032, J Clin Oncol, 33, 7503, 10.1200/jco.2015.33.15_suppl.7503 · DOI
  93. Alley EW, Schellens JH, Santoro A, et al. Single-agent pembrolizumab for patients with malignant pleural mesothelioma (MPM). IASLC 16th World Conference on Lung Cancer; Denver, CO, USA; Sept 6–9, 2015. Abstract 3011.
  94. Ramalingam, 2011, Lung cancer: new biological insights and recent therapeutic advances, CA Cancer J Clin, 61, 91, 10.3322/caac.20102 · DOI · Paper page
  95. Ciuleanu, 2009, Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study, Lancet, 374, 1432, 10.1016/S0140-6736(09)61497-5 · DOI · Paper page
  96. Westeel, 2005, Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer, J Natl Cancer Inst, 97, 499, 10.1093/jnci/dji096 · DOI
  97. Fidias, 2009, Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer, J Clin Oncol, 27, 591, 10.1200/JCO.2008.17.1405 · DOI · Paper page
  98. Brodowicz, 2006, Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial, Lung Cancer, 52, 155, 10.1016/j.lungcan.2006.01.006 · DOI · Paper page
  99. Belani, 2010, Randomized trial of gemcitabine-carboplatin (G-Cb) therapy followed by gemcitabine (G) maintenance or best supportive care (BSC) in advanced NSCLC, J Clin Oncol, 28, 7506, 10.1200/jco.2010.28.15_suppl.7506 · DOI
  100. Perol, 2012, Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer, J Clin Oncol, 30, 3516, 10.1200/JCO.2011.39.9782 · DOI · Paper page
  101. Behera, 2012, Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis, Lung Cancer, 77, 331, 10.1016/j.lungcan.2012.03.019 · DOI
  102. Zhao, 2015, Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804), J Thorac Oncol, 10, 655, 10.1097/JTO.0000000000000445 · DOI

Cited by

See all 3,283

Metadata

Authors
Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y.-L., & Paz-Ares, L.
Venue
The Lancet
Publisher
Elsevier BV
Published
2017-01
Volume
389
Issue
10066
Pages
299-311
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(16)30958-8
OpenAlex
W2508069933
Cited by
3,283
References
46
FWCI
102.75
Type
journal article
Language
en
Open access
bronze
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lung cancer: current therapies and new targeted treatments. https://app.cochat.ai/papers/10.1016/s0140-6736(16)30958-8
The paper
Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y.-L., & Paz-Ares, L. (2017). Lung cancer: current therapies and new targeted treatments. The Lancet. https://doi.org/10.1016/s0140-6736(16)30958-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.